ATRA – atara biotherapeutics, inc. (US:NASDAQ)
Stock Stats
News
12/21
07:51 am
atra
Medium
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
12/20
08:19 am
atra
High
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $25.00 price target on the stock.
12/7
12:40 pm
atra
Medium
Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Positive Post-Trans
11/30
07:10 am
atra
Medium
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
11/27
04:01 pm
atra
Low
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
11/12/2024
04:01 pm
atra
22.2%
BEAT
8/12/2024
05:00 pm
atra
3.2%
MISS
5/9/2024
04:01 pm
atra
-2.9%
BEAT
3/28/2024
08:30 am
atra
-0.8%
BEAT
12/20
08:19 am
Initiates
Buy
Rodman & Renshaw
High
15.4%
12/20
08:19 am
Initiates
Buy
Rodman & Renshaw
High
15.4%
12/20
07:59 am
Initiates
Buy
Rodman & Renshaw
High
15.4%
12/20
06:49 am
Initiates
BUY
RODMAN & RENSHAW
High
20.6%
12/20
06:49 am
Initiates
BUY
RODMAN & RENSHAW
High
20.6%
12/23
04:00 pm
atra
Medium
Form 8-K Atara Biotherapeutics, For: Dec 20
11/20
06:06 pm
atra
High
Form 4 Atara Biotherapeutics, For: Nov 18 Filed by: Henrich Jill
11/20
06:05 pm
atra
High
Form 4 Atara Biotherapeutics, For: Nov 18 Filed by: Hyllengren Eric J
11/20
06:04 pm
atra
Low
Form 4 Atara Biotherapeutics, For: Nov 18 Filed by: Nguyen AnhCo
11/18
05:59 pm
atra
Medium
Form 144 Atara Biotherapeutics, Filed by: Nguyen AnhCo
Show more
Top News Gainers
3/19 Atara Biotherapeutics Inc (NASDAQ: ATRA) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 25.1%
11/7 Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress 11.2%
2/5 Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer 8.5%
8/9 Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 6.1%
9/10 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 6.0%
2/27 Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.8%
3/3 Form 4 Atara Biotherapeutics, For: Mar 01 Filed by: Touchon Pascal 5.8%
7/18 Form 424B5 Atara Biotherapeutics, 5.7%
4/22 Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) 5.7%
12/11 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.5%
Top News Decliners
5/9 Q1/2019 3/31/2019 EPS -1.440 ZacksConsensus -1.480 ActVsEst 0.040 - Beat -20.6%
7/16 Atara Biotherapeutics Announces Plan to Initiate Tab-cel® FDA Biologics License Application Submission Next Year -11.9%
2/21 Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) -10.3%
5/12 Atara Biotherapeutics, Inc. 2019 Q1 - Results - Earnings Call Slides [Seeking Alpha] -8.6%
2/19 Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020 -8.4%
10/29 Atara Biotherapeutics Inc (NASDAQ: ATRA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.7%
5/7 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -7.7%
7/16 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.3%
6/29 Atara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN) -7.2%
8/1 Atara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 8, 2019 -7.1%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3